Global Trend of Survival and Damage of Systemic Lupus Erythematosus: Meta-Analysis and Meta-Regression of Observational Studies from the 1950s to 2000s

Mak, Anselm; Cheung, Mike W.‐L.; Chiew, Hui Jin; Liu, Yang; Ho, Roger

doi:10.1016/j.semarthrit.2011.11.002

Cited by 192 publications

(141 citation statements)

References 30 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…Secondly, mycophenolate mofetil (MMF, 2-3g/day) is as effective as cyclophosphamide in inducing remission in lupus nephritis 4 . The equivalence of cyclophosphamide and MMF, but the better side-effect profile of MMF has been subsequently confirmed in study meta-analyses 63,78 . There is some suggestion MMF may be more effective in patients of a nonwhite European background, possibly because cyclophosphamide is less effective in this group 59 .…”

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 83%

Systemic lupus erythematosus: An update for ophthalmologists

Papagiannuli

Rhodes

Wallace

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a life-threatening multisystem inflammatory condition that may affect almost any part of the eye. We provide an update for the practicing ophthalmologist comprising a systematic review of the recent literature presented in the context of current knowledge of the pathogenesis, diagnosis, and treatment of this condition. We review recent advances in the understanding of the influence of genetic and environmental factors on the development of SLE. Recent changes in the diagnostic criteria for SLE are considered. We assess the potential for novel molecular biomarkers to find a clinical application in disease diagnosis and stratification and in the development of therapeutic agents. We discuss limited forms of SLE and their differentiation from other collagen vascular disorders and review recent evidence underlying the use of established and novel therapeutics in this condition, including specific implications regarding monitoring for ocular toxicity associated with antimalarials.

show abstract

Section: A C C E P T E D Accepted Manuscriptmentioning

confidence: 83%

Systemic lupus erythematosus: An update for ophthalmologists

Papagiannuli

Rhodes

Wallace

et al. 2016

Survey of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…SLE patients sometimes acquire a critical illness that can lead to intensive care unit (ICU) admission. Although the overall survival of SLE patients has improved over time, 1 previous studies have reported high mortality rates of SLE patients in the ICU that range from 29.2 to 56.9%. [2][3][4][5][6][7] There are geographical differences in SLE disease manifestations, outcomes, health care referral systems, and availability of therapy.…”

Section: Introductionmentioning

confidence: 99%

A study of Thai patients with systemic lupus erythematosus in the medical intensive care unit: epidemiology and predictors of mortality

Siripaitoon

Lertwises

Uea-Areewongsa

et al. 2014

Lupus

View full text Add to dashboard Cite

In this retrospective study, we described demographic information, reasons for admission, APACHE II severity scores, complications, mortality rate, causes of death and prognostic factors in 61 Thai patients with systemic lupus erythematosus (SLE) who were admitted to the medical intensive care unit (ICU) over a six-year period. The overall mortality rate during ICU hospitalization was 57% and the most common cause of death was infection, especially in the lower respiratory tract. The mean (SD) APACHE II score was 24.8 (10.8). SLE patients who had an APACHE II score of 20 or more were up to 65% of the patient population and had a significantly lower probability of survival based on Kaplan-Meier results (p = 0.004). The need for vasopressor therapy was significantly higher in patients who did not survive (OR = 6.98, 95% CI = 1.91-25.49). The patients who developed ventilator-associated pneumonia had a numerically higher mortality, which was not statistically significant (OR = 4.17, 95% CI = 0.91-19.03). The use of azathioprine as a steroid-sparing agent for SLE was associated with lower mortality rates (OR = 0.08, 95% CI = 0.01-0.58). Our findings emphasize that Thai SLE patients admitted to the medical ICU has a high mortality rate and early aggressive treatments are warranted.

show abstract

“…[2] The overall SLE survival rates have increased significantly between the 1950s and 2000s, from 74.8% to 94.8% and 63.2% to 91.4% for the overall 5-year and 10-year survival, respectively. [3] These improved outcomes are thought to be due to a combination of earlier recognition of mild disease and better approaches to therapy.…”

mentioning

confidence: 99%